0
November 1985, Vol 139, No. 11 >
Article | November 1985

Imipenem/Cilastatin for the Treatment of Infections in Hospitalized Children FREE

Gershon Alpert, MD; Ron Dagan, MD; Edward Connor, MD; Joseph M. Campos, PhD; A. Michael Bloh; Keith R. Powell, MD; Stanley A. Plotkin, MD
[+] Author Affiliations

Reprint requests to The Children's Hospital National Medical Center, Microbiology Laboratory, 111 Michigan Ave NW, Washington, DC 20010 (Dr Campos).


Am J Dis Child. 1985;139(11):1153-1156. doi:10.1001/archpedi.1985.02140130091038.
Text Size: A A A
Published online
Article
References
Comments

• Imipenem is the first of a new class of βlactam antimicrobial agents with potent in vitro activity against most bacterial pathogens that cause infections in children. We studied, prospectively, the clinical efficacy and toxicity of imipenem/cilastatin in 40 children with proved or suspected bacterial infection. A dose of 100 mg/kg/day of imipenem was given to children younger than 3 years of age, while children older than 3 years of age received 60 mg/kg/day. Twenty-nine organisms were isolated from 26 patients. Infections treated included cellulitis, osteomyelitis, septic arthritis, lymphadenitis, renal infections, wound infections, and pneumonia. Bacteria isolated included Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Pseudomonas aeruginosa. All patients responded favorably to treatment, with defervescence and improvement of symptoms. All of the infecting bacteria were susceptible to imipenem. Imipenem/cilastatin was well tolerated, with no serious side effects, and appeared to be an effective and safe antimicrobial agent in the treatment of the population studied.

(AJDC 1985;139:1153-1156)

REFERENCES

1 +
Kesado T, Hashizume T, Yoshinari A:  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics . Antimicrob Agents Chemother 1980;;17:912-917.
2 +
Kropp H, Sundelof JG, Kahan JS, et al:  MK 0787 (N-formimidoyl thienamycin): Evaluation of in vitro and in vivo activities . Antimicrob Agents Chemother 1980;;17:993-1000.
3 +
Tally FP, Jacobus NV, Gorbach SL:  In vitro activity of N-formimidoyl thienamycin (MK 0787) . Antimicrob Agents Chemother 1980;;18: 642-644.
4 +
Tutlane VA, McCloskey RV, Trent JA:  In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime and cefoperazone . Antimicrob Agents Chemother 1981;;20:140-143.
5 +
Cherubin CE, Corrado ML, Sierra MF, et al:  Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin . Antimicrob Agents Chemother 1981;;20:553-555.
6 +
Neu HC, Labthavikul P:  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability . Antimicrob Agents Chemother 1982;;21: 180-187.
7 +
Cullmann W, Opferkuch W, Stieglitz M, et al:  A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK 0787) with those of other recently developed beta-lactam derivatives . Antimicrob Agents Chemother 1982;;22:302-307.
8 +
Owens WE, Finegold SM:  Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan and N-formimidoyl thienamycin . Antimicrob Agents Chemother 1983;;23:626-629.
9 +
Fass RJ:  Comparative in vitro activities of third-generation cephalosporins . Arch Intern Med 1983;;143:1743-1745.
10 +
Gravallese DA, Musson DG, Pauliukonis LT, et al:  Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography: Comparison with microbiological method and stability . J Chromatogr 1984;;310:71-84.
11 +
Witte JL, Sapico FL, Canawati HN:  In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin . Antimicrob Agents Chemother 1982;;22:906-908.
12 +
Livingston WK, Elliott AM, Cobbs CG:  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens and Enterococcus spp . Antimicrob Agents Chemother 1981;;19: 114-116.
13 +
Blumenthal RM, Raeder R, Takemoto CD, et al:  Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci . Antimicrob Agents Chemother 1983;;24:61-69.
14 +
Kropp H, Sundelof JG, Hajdu R, et al:  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I . Antimicrob Agents Chemother 1982;;22:62-70.
15 +
Norrby SR, Alestig K, Bjorengard B, et al:  Urinary recovery of N-formimidoyl thienamycin (MK 0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors . Antimicrob Agents Chemother 1983;; 23:300-307.
16 +
Eron LJ, Hixon DL, Park CH, et al:  Imipenem versus moxalactam in the treatment of serious infections . Antimicrob Agents Chemother 1983;;24:841-846.
17 +
 Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections: Report from a Scandinavian study group . Lancet 1984;;1:868-871.
18 +
Winston OJ, McGrattan MA, Busutil RW:  Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections . Antimicrob Agents Chemother 1984;;26:673-677.

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

References

1 +
Kesado T, Hashizume T, Yoshinari A:  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics . Antimicrob Agents Chemother 1980;;17:912-917.
2 +
Kropp H, Sundelof JG, Kahan JS, et al:  MK 0787 (N-formimidoyl thienamycin): Evaluation of in vitro and in vivo activities . Antimicrob Agents Chemother 1980;;17:993-1000.
3 +
Tally FP, Jacobus NV, Gorbach SL:  In vitro activity of N-formimidoyl thienamycin (MK 0787) . Antimicrob Agents Chemother 1980;;18: 642-644.
4 +
Tutlane VA, McCloskey RV, Trent JA:  In vitro comparison of N-formimidoyl thienamycin, piperacillin, cefotaxime and cefoperazone . Antimicrob Agents Chemother 1981;;20:140-143.
5 +
Cherubin CE, Corrado ML, Sierra MF, et al:  Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin . Antimicrob Agents Chemother 1981;;20:553-555.
6 +
Neu HC, Labthavikul P:  Comparative in vitro activity of N-formimidoyl thienamycin against gram-positive and gram-negative aerobic and anaerobic species and its beta-lactamase stability . Antimicrob Agents Chemother 1982;;21: 180-187.
7 +
Cullmann W, Opferkuch W, Stieglitz M, et al:  A comparison of the antibacterial activities of N-formimidoyl thienamycin (MK 0787) with those of other recently developed beta-lactam derivatives . Antimicrob Agents Chemother 1982;;22:302-307.
8 +
Owens WE, Finegold SM:  Comparative in vitro susceptibilities of anaerobic bacteria to cefmenoxime, cefotetan and N-formimidoyl thienamycin . Antimicrob Agents Chemother 1983;;23:626-629.
9 +
Fass RJ:  Comparative in vitro activities of third-generation cephalosporins . Arch Intern Med 1983;;143:1743-1745.
10 +
Gravallese DA, Musson DG, Pauliukonis LT, et al:  Determination of imipenem (N-formimidoyl thienamycin) in human plasma and urine by high-performance liquid chromatography: Comparison with microbiological method and stability . J Chromatogr 1984;;310:71-84.
11 +
Witte JL, Sapico FL, Canawati HN:  In vitro susceptibility of methicillin-resistant and methicillin-susceptible Staphylococcus aureus strains to N-formimidoyl thienamycin . Antimicrob Agents Chemother 1982;;22:906-908.
12 +
Livingston WK, Elliott AM, Cobbs CG:  In vitro activity of N-formimidoyl thienamycin (MK0787) against resistant strains of Pseudomonas aeruginosa, Staphylococcus epidermidis, Serratia marcescens and Enterococcus spp . Antimicrob Agents Chemother 1981;;19: 114-116.
13 +
Blumenthal RM, Raeder R, Takemoto CD, et al:  Occurrence and expression of imipemide (N-formimidoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci . Antimicrob Agents Chemother 1983;;24:61-69.
14 +
Kropp H, Sundelof JG, Hajdu R, et al:  Metabolism of thienamycin and related carbapenem antibiotics by the renal dipeptidase, dehydropeptidase-I . Antimicrob Agents Chemother 1982;;22:62-70.
15 +
Norrby SR, Alestig K, Bjorengard B, et al:  Urinary recovery of N-formimidoyl thienamycin (MK 0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors . Antimicrob Agents Chemother 1983;; 23:300-307.
16 +
Eron LJ, Hixon DL, Park CH, et al:  Imipenem versus moxalactam in the treatment of serious infections . Antimicrob Agents Chemother 1983;;24:841-846.
17 +
 Imipenem/cilastatin versus gentamicin/clindamycin for treatment of serious bacterial infections: Report from a Scandinavian study group . Lancet 1984;;1:868-871.
18 +
Winston OJ, McGrattan MA, Busutil RW:  Imipenem therapy of Pseudomonas aeruginosa and other serious bacterial infections . Antimicrob Agents Chemother 1984;;26:673-677.

Correspondence

Submit a Letter
CME
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Clear Answers | Save For Later
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2013 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems